ConductScience.org, home

Paper17488686

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S and 23 others. Haematologica, 2007. Cited by 74 papers, by iCite.

Cite this record

ConductScience Library. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Papers, record 17488686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17488686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
PubMed
Journal
Haematologica
PubMed
Year
2007
PubMed
Publication types
Journal Article, Multicenter Study
PubMed
Citations, by iCite
74
iCite
Relative citation ratio, by iCite
1.79
iCite
Revised in PubMed
2019-06-08
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vigouroux SStéphane
2Michallet MMauricette
3Porcher RRaphaël
4Attal MMichel
5Ades LLionel
6Bernard MMarc
7Blaise DDidier
8Tabrizi RReza
9Garban FFrédéric
10Cassuto JPJill-Patrice
11Chevalier PPatrice
12Facon TThierry
13Ifrah NNorbert
14Renaud MMarc
15Tilly HHervé
16Vernant JPJean-Paul
17Kuentz MMathieu
18Bourhis JHJean-Henri
19Bordigoni PPierre
20Deconinck EEric

Source PubMed

See all 24 authorsDownload CSV of authors

Topics36

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematopoietic Stem Cell TransplantationMajor topic
Lymphoma, Non-HodgkinMajor topic
Transplantation ConditioningMajor topic
Adult
Aged
Antibodies, Monoclonal
Antilymphocyte Serum
Antineoplastic Combined Chemotherapy Protocols
Busulfan
Carmustine
Combined Modality Therapy
Cyclophosphamide
Cytarabine
Data Collection
Disease-Free Survival
Etoposide
Female
France
Graft vs Host Disease
Graft vs Leukemia Effect
Humans
Kaplan-Meier Estimate
Male
Melphalan
Middle Aged
Proportional Hazards Models
Remission Induction
Retrospective Studies
Salvage Therapy
Survival Analysis
Survival Rate
T-Lymphocytes
Transplantation, Homologous
Treatment Outcome
Vidarabine
Whole-Body Irradiation

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01208896Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular LymphomaBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17488679Current role of allogeneic stem cell transplantation in follicular lymphoma.https://conductscience.org/library/papers/17488679

Source PubMed

Download CSV of comments and corrections

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 74 citations.

PMIDTitleJournalYearIn PapersSource
29424927Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.Cancer2018https://conductscience.org/library/papers/29424927PubMed
27175243Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.Leuk Suppl2012https://conductscience.org/library/papers/27175243PubMed
26855152Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.Bone Marrow Transplant2016https://conductscience.org/library/papers/26855152PubMed
25985053Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Bone Marrow Transplant2015https://conductscience.org/library/papers/25985053PubMed
25190696Non-Hodgkin's lymphomas, version 4.2014.J Natl Compr Canc Netw2014https://conductscience.org/library/papers/25190696PubMed
24534109
Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.
Biol Blood Marrow Transplant2014https://conductscience.org/library/papers/24534109PubMed
24315843
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
Biol Blood Marrow Transplant2014https://conductscience.org/library/papers/24315843PubMed
24043582Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.Int J Hematol2013https://conductscience.org/library/papers/24043582PubMed
23935024
Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.
Haematologica2014https://conductscience.org/library/papers/23935024PubMed
23813647Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Haematologica2013https://conductscience.org/library/papers/23813647PubMed
23771004
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
Bone Marrow Transplant2013https://conductscience.org/library/papers/23771004PubMed
23691438Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status.Cancer Biol Med2013https://conductscience.org/library/papers/23691438PubMed
23556071Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.Ther Adv Hematol2011https://conductscience.org/library/papers/23556071PubMed
23380340Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.Biol Blood Marrow Transplant2013https://conductscience.org/library/papers/23380340PubMed
23222387Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.Bone Marrow Transplant2013https://conductscience.org/library/papers/23222387PubMed
23063143Management of indolent lymphoma: where are we now and where are we going.Blood Rev2012https://conductscience.org/library/papers/23063143PubMed
22522568Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.Bone Marrow Transplant2012https://conductscience.org/library/papers/22522568PubMed
22312100Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.J Clin Oncol2012https://conductscience.org/library/papers/22312100PubMed
21641099Stem cell transplantation for indolent lymphoma: a reappraisal.Blood Rev2011https://conductscience.org/library/papers/21641099PubMed
21358679Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.Bone Marrow Transplant2012https://conductscience.org/library/papers/21358679PubMed

See all 36 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17488686

GET https://conductscience.org/api/papers/v1/17488686/authors?page=2